康莱特注射液联合DC-CIK细胞对恶性肿瘤患者免疫指标影响的临床研究

Clinical study on influence of Kanglaite injection combined DC-CIK cells on immune index among patients with malignant tumor

目的观察康莱特注射液联合DC-CIK细胞免疫治疗常见恶性肿瘤患者的细胞免疫功能及疗效,探讨康莱特注射液在恶性肿瘤生物细胞免疫治疗中的作用。方法选取符合西医诊断标准及中医气阴两虚或脾虚湿困型证候诊断标准的恶性肿瘤患者75例,随机分为对照组(30例)和治疗组(35例)。对照组予DC-CIK细胞治疗,治疗组予DC-CIK细胞联合康莱特注射液治疗。观察两组患者治疗前后T细胞亚群、临床疗效等。用SPSS 13.0对数据进行t检验和χ~2检验。结果联合治疗组患者经过治疗后,CD3^+、CD4^+CD56^+、CD8^+T淋巴细胞比率均较治疗前、对照组治疗后显著升高,差异均有统计学意义(P<0.05)。对照组治疗有效率为40%,肿瘤控制率为48.57%;联合治疗组治疗率有效为57.50%,肿瘤控制率为80.00%。两组治疗有效率比较差异无统计学意义(χ~2=1.4655,P>0.05),肿瘤控制率比较差异有统计学意义(χ~2=4.2834,P<0.05)。结论采用康莱特注射液联合DC-CIK治疗方法能够提高免疫细胞功能、提高疗效,具有较强的临床推广价值。

[Observation] To observe the cellular immune function and curative effect of Kanglaite injection combined DC-CIK c, ellular immunity treating patients with malignant tumor, and explore the role of Kanglaitc injection in malignant tumor biological cellular immune therapy.[Methods]A total of 75 cases of malignant tumor which accorded with western medicine diagnostic criteria and traditional Chinese medicine qiyin deficiency or spleen deficiency with damp harassment diagnostic criteria were selected and randomly divided into control group （30 cases） and treatment group（30 cases）. The control group was given DC-CIK cell therapy, and treatment group was given DC-CIK combined Kanglaite injection therapy. The T cell subgroup and clinical curative effect of two groups before and after treatment were observed. The t test and chi-square test were carried out by SPSS 13.0. [Results] After treatment, the ratio of CD3＋, CD4＋, CD56＋, CD8＋ T lymphocyte of treatment group were higher than those of before treatment and control group, the differences were statistically significant（P〈0.05 ）. The effective rates of treatment in control group and treatment group were 40.00% and 57.50% respectively, thedifference was not statistically significant （χ2 =1.4655 ,P〉0.05）. And the tumor control rates were 48.57% and 80.00% respectively, the difference was statistically significant （χ2 =4.2834, P〈0.05）. [Conclusion] The Kanglaite injection combined DC-CIK therapeutic method can improve immune cell function and curative effect, which has strong clinical popularization value.